Bayer, a global life sciences company, has announced a new strategic alliance focused on clinical trials collaboration with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, establishing Bayer’s first alliance of its kind with an academic medical centre. The initiative reflects a shared commitment to accelerating clinical research through stronger collaboration between industry and academic medicine.
The alliance is intended to improve clinical trial efficiency, expand patient access to investigational therapies, and advance new medical discoveries. Initial focus areas for the alliance will include research studies in oncology, cardiovascular disease, chronic kidney disease, neurodegenerative disease, cell and gene therapy, women’s health, and ophthalmology.
The alliance is designed to:
Expand clinical trial infrastructure to execute more studies faster.
Facilitate earlier and broader patient access to investigational therapies.
Foster collaboration between industry, academic researchers, clinicians and health systems.
Advancing Clinical Trials Through Collaboration
The alliance will support innovative approaches to clinical trial design and implementation, enhanced patient enrollment, and expanded research operations. By combining Bayer’s drug development expertise with the extensive academic and clinical strengths of the University of Colorado Anschutz (CU Anschutz), UCHealth and Children’s Hospital Colorado (Children’s Colorado), the collaboration aims to expedite clinical research and bring lifesaving experimental therapies to more patients.
“Bayer is committed to bringing first-in-class or best-in-class therapies to market for the people who need them,” said Christoph Koenen, Head, Clinical Development & Operations for Bayer. “Our alliance with this renowned academic medical centre brings together several leading organisations to deliver new, innovative ways to advance clinical research for the benefit of patients.”
The alliance will also support clinical trial infrastructure while facilitating scientific collaboration to advance new therapies and medical innovations. Examples include:
Access to clinical, scientific and operational experts to support trial design, planning and clinical implementation after drug approval.
Expanded administrative and data science infrastructure to speed up clinical trial launch time.
Access to clinical data to support trial enrollment, including identifying the patient populations most likely to benefit from treatment.
“We are honoured to be selected as Bayer’s first academic medical centre partner for clinical trials,” said Adit Ginde, MD, MPH, senior associate dean for clinical research and professor of emergency medicine at the CU Anschutz School of Medicine. “This strategic alliance combines our deep experience in clinical trials, expert patient care, and renowned health system partners with Bayer’s extensive drug development infrastructure to speed the approval time of effective treatments for local, national and global implementation.”
